Serum Institute

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield

The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to eight to 16 weeks, from the current gap of 12 to 16

SII asks Centre to reduce gap between second and precaution COVID-19 dose; what is the global mandate for booster shot

The current gap between the two doses is nine months. The Centre had revised the guidelines for officials on election duty who can now be vaccinated 90 days after their second dose

Union Budget 2022: Why Centre has reduced COVID-19 vaccine budget to Rs 5,000 crore

Experts are of the opinion that the reduction in allocation of funds hints that the Centre has done its job of providing free vaccines across the country and people may have to shell out for booster shots

Govt panel recommends market approval for Covaxin, Covishield but with conditions

The recommendations will be sent to the Drugs Controller General of India for final approval. Covishield and Covaxin were granted emergency use authorisation on 3 January, 2021

Serum Institute's Covishield vaccine gets nod from France for travel

The move to accept visitors vaccinated with AstraZeneca's vaccine made by SII came after a global outcry over the fact that the EU's selective approval was discriminatory

SII may roll out Novavax's Covovax COVID-19 vaccine by Sept; key updates on India's vaccine drive

Novavax said that the efficacy of its vaccine was 93.2 percent against Variants of Concern (VoC) and Variants of Interest (VoI), which represented 82 percent of the cases during trials

Novavax vaccine leaves Covishield, Covaxin way behind with 90.4% overall efficacy

Likely to be priced at Rs 1,114 per dose in India, Novavax vaccine will be a two-dose jab like the other vaccines

Serum Institute of India gets DCGI's nod to manufacture Sputnik V in India for test, analysis

The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology in Moscow for developing Sputnik V at its licensed Hadapsar facility

Serum institute seeks permission to manufacture Sputnik V vaccine in India

SII said it will be able to manufacture and supply 10 crore Covishield doses in June while also manufacturing Novavax.

Serum institute will deliver COVID-19 vaccines to COVAX, other nations by end-2021

COVAX is dependent on nearly one billion doses of the AstraZeneca vaccine being made by the Serum Institute.